Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BVS | Class A Common Stock | Award | +2.78M | 2.78M | Oct 29, 2021 | Direct | F1 |
Id | Content |
---|---|
F1 | Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each share of Misonix Inc. ("Misonix") common stock (a "Misonix Option") that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of the Company's Class A Common Stock, $0.001 par value per share ("Bioventus Shares"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. |